Clinical trial
Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced…
NCT00497458 · Havah Therapeutics Pty Ltd, Industry · Unknown status
Key facts
| NCT number | NCT00497458 |
|---|---|
| Title | Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects |
| Official title | Phase II Study of Testosterone Replacement in Women Experiencing Aromatase Inhibitor Side-Effects in Adjuvant Therapy for Breast Cancer |
| Acronym | ART2 |
| Lead sponsor | Havah Therapeutics Pty Ltd, Industry |
| Collaborators | AstraZeneca Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Arthralgia, Osteoporosis |
| Intervention type | Drug |
| Interventions | Testosterone |
| Enrollment | 90 |
| Start date | Jul 1, 2007 |
| Primary completion | Apr 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jul 6, 2007 |
| Last update posted | Apr 9, 2009 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: